The NeoTYPE® Gastric Tumor Profile analyzes 39 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of all results to help guide treatment decisions. If Pan-TRK IHC is expressed or equivocal, reflex to either NTRK NGS Fusion Panel (Default) or NTRK 1-3 FISH Panel will be added. A microsatellite instability (MSI) NGS result of “indeterminate” will create a reflex to MSI by PCR as long as the tumor percentage is ≥40% and paired normal tissue is available.
NGS (33 genes + 2 biomarkers): AKT1, ARID1A, BRAF, CDH1, CDKN2A, EGFR, ERBB2, ERBB3, ERBB4, FGFR1, FGFR2, FGFR3, HRAS, KIT, KRAS, MET, Microsatellite Instability (MSI), MLH1, MSH2, MSH6, NOTCH1, NRAS, PDGFRA, PIK3CA, PMS2, PREX2, PTEN, RNF43, SMAD4, SMO, SRC, TGFBR2, TERT Promoter, TP53, Tumor Mutation Burden (TMB)
FISH (2 FISH): MET, PTEN (tech-only available)
IHC (6 biomarkers): MMR (opt-out available), PD-L1 LDT, Pan-TRK (tech-only available for MMR and PD-L1)
The NeoTYPE® Gastric Tumor Profile characterizes gastric tumors of any histological subtype for the most significant genetic changes relevant to therapy decisions, prognosis, and clinical research. It is appropriate for patients with newly-diagnosed or recurrent disease, and for patients with resistant disease to explore options in clinical trials.
- FFPE tissue: Paraffin block preferred. Please use 10% buffered formalin fixative. Do not use zinc fixatives.
Use cold pack for transport, making sure cold pack is not in direct contact with specimen. All slides can be packed at room temperature
14 days; add 1-3 days if reflexed to NTRK NGS Fusion Profile